Table 4.
Adjusted slope for Age, Severity and SRS
| Age | Severity | SRS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | Male | Female | |||||||
| Analyte | Slope | Pr(>Chisq) | Slope | Pr(>Chisq) | Slope | Pr(>Chisq) | Slope | Pr(>Chisq) | Slope | Pr(>Chisq) | Slope | Pr(>Chisq) |
| Basic FGF | − 0.01 | 0.89 | 0.00 | 0.98 | − 0.04 | 0.39 | − 0.06 | 0.37 | 0.00 | 0.97 | 0.00 | 0.97 |
| Eotaxin | − 0.03 | 0.16 | − 0.02 | 0.77 | − 0.06 | 0.13 | − 0.11 | 0.07 | 0.00 | 0.97 | −0.01 | 0.85 |
| G-CSF | 0.02 | 0.48 | 0.04 | 0.55 | −0.03 | 0.48 | − 0.03 | 0.68 | 0.01 | 0.96 | 0.00 | 0.97 |
| GM-CSF | − 0.01 | 0.85 | 0.02 | 0.85 | −0.01 | 0.89 | − 0.01 | 0.87 | 0.01 | 0.96 | 0.00 | 0.98 |
| IFN-γ | − 0.02 | 0.77 | 0.00 | 0.98 | − 0.04 | 0.34 | − 0.07 | 0.35 | 0.00 | 0.97 | − 0.01 | 0.97 |
| IL-10 | − 0.03 | 0.16 | − 0.02 | 0.85 | − 0.01 | 0.89 | − 0.08 | 0.22 | − 0.01 | 0.90 | − 0.01 | 0.97 |
| IL-12p70 | −0.04 | 0.07 | 0.00 | 0.98 | − 0.02 | 0.68 | − 0.12 | 0.05 | −0.01 | 0.88 | 0.00 | 0.97 |
| IL-13 | 0.01 | 0.77 | − 0.01 | 0.89 | − 0.01 | 0.75 | − 0.05 | 0.44 | 0.00 | 0.97 | − 0.01 | 0.70 |
| IL-15 | 0.04 | 0.04* | 0.04 | 0.48 | 0.00 | 0.96 | 0.04 | 0.54 | 0.00 | 0.97 | 0.00 | 0.97 |
| IL-17A | − 0.02 | 0.77 | 0.00 | 0.99 | − 0.03 | 0.48 | − 0.04 | 0.54 | 0.00 | 0.97 | 0.00 | 0.97 |
| IL-1β | − 0.02 | 0.72 | 0.02 | 0.85 | −0.06 | 0.15 | − 0.20 | < 0.001* | −0.01 | 0.88 | 0.01 | 0.85 |
| IL-1RA | − 0.01 | 0.85 | 0.02 | 0.77 | − 0.04 | 0.35 | − 0.08 | 0.22 | 0.00 | 0.97 | 0.00 | 0.97 |
| IL-2 | 0.00 | 0.98 | 0.01 | 0.87 | 0.00 | 1.00 | −0.04 | 0.57 | 0.00 | 0.97 | 0.00 | 0.97 |
| IL-4 | 0.00 | 0.98 | 0.01 | 0.87 | −0.04 | 0.37 | −0.07 | 0.31 | 0.00 | 0.97 | 0.00 | 0.97 |
| IL-5 | − 0.02 | 0.77 | 0.00 | 0.98 | − 0.05 | 0.22 | − 0.06 | 0.39 | 0.00 | 0.97 | − 0.01 | 0.85 |
| IL-6 | − 0.01 | 0.84 | 0.02 | 0.85 | − 0.04 | 0.39 | − 0.06 | 0.39 | 0.00 | 0.97 | 0.00 | 0.97 |
| IL-7 | 0.00 | 0.95 | 0.01 | 0.98 | − 0.04 | 0.34 | − 0.06 | 0.35 | 0.00 | 0.97 | 0.00 | 0.97 |
| IL-8 | − 0.06 | 0.01* | 0.02 | 0.77 | − 0.05 | 0.22 | − 0.29 | < 0.001* | 0.00 | 0.97 | 0.02 | 0.03* |
| IL-9 | − 0.01 | 0.85 | 0.00 | 0.98 | − 0.01 | 0.74 | 0.00 | 1.00 | − 0.01 | 0.90 | 0.00 | 0.97 |
| IP-10 | − 0.04 | 0.09 | − 0.10 | 0.001* | − 0.05 | 0.22 | − 0.02 | 0.74 | − 0.01 | 0.80 | − 0.02 | 0.21 |
| MCP-1 | 0.01 | 0.91 | 0.02 | 0.84 | − 0.03 | 0.48 | − 0.05 | 0.48 | 0.00 | 0.97 | 0.00 | 0.97 |
| MIP-1α | − 0.01 | 0.84 | − 0.01 | 0.89 | − 0.03 | 0.48 | − 0.03 | 0.60 | 0.00 | 0.97 | 0.00 | 0.97 |
| MIP-1β | − 0.05 | 0.01* | − 0.03 | 0.63 | − 0.01 | 0.75 | − 0.16 | 0.01* | − 0.01 | 0.85 | 0.01 | 0.97 |
| PDGF-BB | − 0.04 | 0.08 | − 0.02 | 0.85 | − 0.08 | 0.03* | − 0.16 | 0.01* | −0.01 | 0.80 | 0.01 | 0.85 |
| RANTES | − 0.01 | 0.88 | 0.01 | 0.87 | − 0.02 | 0.54 | − 0.09 | 0.20 | 0.00 | 0.97 | 0.01 | 0.85 |
| TNF-α | −0.02 | 0.72 | 0.00 | 0.99 | − 0.05 | 0.22 | − 0.05 | 0.44 | 0.00 | 0.97 | 0.00 | 0.97 |
| VEGF | − 0.04 | 0.09 | 0.01 | 0.98 | − 0.03 | 0.48 | − 0.13 | 0.03* | 0.00 | 0.97 | 0.00 | 0.97 |
Chisq tests: p value adjustment method: false discovery rate
Abbreviations: Basic.FGF basic fibroblast growth factor, G.CSF granulocyte colony-stimulating factor, GM granulocyte macrophage colony-stimulating factor, IFN. γ interferon-γ, IL interleukin, IL.1β IL-1 beta, IL.1RA, IL-1 receptor antagonist, IP interferon gamma-inducible protein 10, MCP.1 monocyte chemotactic protein-1, MIP.1α macrophage inflammatory protein-1α, MIP.1β macrophage inflammatory protein-1β, PDGF.BB Platelet derived growth factor-BB, RANTES regulated on activation, normal T cell expressed and secreted, TNF. α tumor necrosis factor-α, VEGF vascular endothelial growth factor. * indicates significant difference at P < 0.05 or better